Horiba ABX has announced work is to commence shortly on a new euro8 million consolidated reagent plant in response to the company's continued growth in haematology and clinical chemistry
To be located in Montpellier in the south of France, the state-of-the-art facilities will span some 4400m2 and almost double capacity to 13,000 tonnes of reagents per annum, compared to the current 7000 tonnes.
The new plant will also enable Horiba ABX to centralise all its other activities related to reagents - research, commercial operations and logistics - on one site.
According to Guy de Lanversin, general manager of Horiba ABX, the investment represents both a sign of confidence in the market and determination to improve service levels to an expanding customer base: "Over the last few years, through a combination of hard work by our highly professional staff and an innovative product range, Horiba ABX has both maintained its leading position in haematology in Europe and made inroads into the highly competitive clinical chemistry market.
"We regard the development, manufacture and supply of high quality reagents as central to the continuation of our success.
"By expanding our production capacity for both haematology and biochemistry reagents, as well as bringing research and development, and logistics under one roof, this major new investment will enable us to achieve our goal and create a flagship site for Horiba ABX".
The new facility is due to come on line in early 2008.
